A new study presented at the International Conference on Molecular Targets and
Cancer Therapeutics, held in Philadelphia, shows that phenoxodiol significantly
delays tumor progression in men suffering from late-stage hormone refractory
The antitumor effect in this Phase Ib/IIa trial was dose-dependent. The trial was designed to end after 24 weeks of treatment, but had to be extended to the current 90 weeks because of the unexpected extended survival in some patients. Patients have been able to remain on phenoxodiol for this extended time without any evidence of toxicity.
Researchers administered various doses of phenoxodiol to men with metastatic, hormone-refractory prostate cancer to establish what level of anticancer effect the oral dosage form of this drug would provide and whether there was a dose-dependent effect. The phenoxodiol was administered in monthly treatment cycles comprised of three doses daily for 21 consecutive days followed by seven days without treatment.